The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 08, 2018

Filed:

Sep. 04, 2014
Applicant:

Korea Institute of Radiological & Medical Sciences, Seoul, KR;

Inventors:

Sang Gu Hwang, Seoul, KR;

Hong Shik Yun, Seoul, KR;

Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C12N 15/11 (2006.01); C07H 21/04 (2006.01); C12N 15/113 (2010.01); A61K 31/475 (2006.01); A61K 31/704 (2006.01); A61K 31/7088 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); C07K 16/22 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C12N 15/1136 (2013.01); A61K 31/475 (2013.01); A61K 31/704 (2013.01); A61K 31/7088 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); C07K 16/22 (2013.01); A61K 2039/505 (2013.01); C07K 2317/76 (2013.01); C12N 2310/14 (2013.01); C12N 2320/31 (2013.01);
Abstract

The present invention relates to a pharmaceutical composition for treating a radiation- or drug-resistant cancer, containing an agent capable of inhibiting the expression of hepatoma-derived growth factor (HDGF)-related protein-3 (HRP-3), a method of treating a radiation- or drug-resistant cancer by administering the pharmaceutical composition, and the use of an HRP-3 inhibitor for preparing an agent for treating a radiation- or drug-resistant cancer. The use of the pharmaceutical composition of the present invention enables to treat a resistant cancer in combination with a conventional anticancer chemotherapy or radiotherapy. Accordingly, the pharmaceutical composition of the present invention can reduce both the costs for developing anticancer agents against resistant cancers and the costs for treating cancers in patients, thus being useful for the economic and effective treatment of resistant cancers.


Find Patent Forward Citations

Loading…